Efficacy of Methylsulfonylmethane Supplementation on Oste... | NCT01188213

Studies
Efficacy of Methylsulfonylmethane Supplementation on Osteoarthritis of The Knee: A Randomized Controlled Study

NCT01188213

Sponsor

Assaf-Harofeh Medical Center

Status

Completed

Last Update Posted

Aug 25, 2010Estimated

Enrollment

Not provided

Phase

Not Applicable

Conditions

Knee Osteoarthritis

Interventions

Methylsulfonylmethane (MSM)

Countries

Not provided

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

May 2005

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Not provided

Primary Completion Date

Not provided

Completion Date

Not provided

First Submitted Date

Aug 21, 2010

First Submission Date that Met QC Criteria

Aug 24, 2010

First Posted Date

Aug 25, 2010Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Aug 24, 2010

Last Update Posted Date

Aug 25, 2010Estimated

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not Applicable

Interventional Study Design

No data available

No data is available for this block.

Biospecimen

No data available

No data is available for this block.

Enrollment

Not provided

Label	Type	Description	Intervention Names
Purified MSM	Experimental		Dietary Supplement: Methylsulfonylmethane (MSM)

Name	Type	Description	Arm Group Labels	Other Names
Methylsulfonylmethane (MSM)	Dietary Supplement		Purified MSM

Measure	Description	Time Frame
WOMAC questionnaire

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

symptomatic knee OA for at least 6 months according to the clinical criteria of the American College of Rheumatology (ACR)
radiographic confirmed knee OA according to the Kellgren & Lawrence scale

Exclusion Criteria:

acute septic arthritis
inflammatory arthritis
any other type of arthritis
history of knee buckling or recent knee injury
lack of physical or mental bility to perform or comply with the treatment procedure
diabetes mellitus
fibromyalgia or other chronic pain syndromes
concurrent anti-coagulant/anti-platelet drugs
arthroscopy or intra-articular injections in the previous 3 months

Accepts Healthy Volunteers

Not provided

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

40 Years

Maximum Age

70 Years

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
21708034	Derived	Debbi EM, Agar G, Fichman G, Ziv YB, Kardosh R, Halperin N, Elbaz A, Beer Y, Debi R. Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study. BMC Complement Altern Med. 2011 Jun 27;11:50. doi: 10.1186/1472-6882-11-50.

ID	Term
D010003	Osteoarthritis
D001168	Arthritis
D007592	Joint Diseases
D009140	Musculoskeletal Diseases